Eli Lilly and Co
Find Ratings Reports
-0.17 |
-0.21%
LILLY (ELI) & CO's gross profit margin for the second quarter of its fiscal year 2016 has decreased when compared to the same period a year ago. The company has grown its sales and net income during the past quarter when compared with the same quarter a year ago, and although its growth in net income has outpaced the industry average, its revenue growth has not. LILLY (ELI) & CO has average liquidity. Currently, the Quick Ratio is 1.00 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
During the same period, stockholders' equity ("net worth") has remained unchanged from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
| Income Statement | Q2 FY16 | Q2 FY15 |
|---|---|---|
| Net Sales ($mil) | 5404.8 | 4978.7 |
| EBITDA ($mil) | 1355.0 | 1392.3 |
| EBIT ($mil) | 981.3 | 1023.8 |
| Net Income ($mil) | 747.7 | 600.8 |
| Balance Sheet | Q2 FY16 | Q2 FY15 |
|---|---|---|
| Cash & Equiv. ($mil) | 3934.8 | 4230.9 |
| Total Assets ($mil) | 36475.3 | 36036.6 |
| Total Debt ($mil) | 9331.3 | 7999.4 |
| Equity ($mil) | 14637.3 | 14670.3 |
| Profitability | Q2 FY16 | Q2 FY15 |
|---|---|---|
| Gross Profit Margin | 79.81 | 84.3 |
| EBITDA Margin | 25.07 | 27.96 |
| Operating Margin | 18.16 | 20.56 |
| Sales Turnover | 0.56 | 0.54 |
| Return on Assets | 6.76 | 5.71 |
| Return on Equity | 16.84 | 14.03 |
| Debt | Q2 FY16 | Q2 FY15 |
|---|---|---|
| Current Ratio | 1.54 | 1.5 |
| Debt/Capital | 0.39 | 0.35 |
| Interest Expense | 57.2 | 50.2 |
| Interest Coverage | 17.16 | 20.39 |
| Share Data | Q2 FY16 | Q2 FY15 |
|---|---|---|
| Shares outstanding (mil) | 1103.84 | 1108.54 |
| Div / share | 0.51 | 0.5 |
| EPS | 0.71 | 0.56 |
| Book value / share | 13.26 | 13.23 |
| Institutional Own % | n/a | n/a |
| Avg Daily Volume | 3713525.0 | 3949276.0 |
BUY. LILLY (ELI) & CO's P/E ratio indicates a premium compared to an average of 29.47 for the Pharmaceuticals industry and a premium compared to the S&P 500 average of 25.19. To use another comparison, its price-to-book ratio of 6.13 indicates a significant premium versus the S&P 500 average of 2.82 and a significant discount versus the industry average of 19.66. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.
| Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY 35.04 | Peers 29.47 | LLY 28.80 | Peers 20.98 | |||||||||||||||||||||
|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations. LLY is trading at a premium to its peers. |
Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. LLY is trading at a significant premium to its peers. |
|||||||||||||||||||||||
| Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
| LLY 19.82 | Peers 15.05 | LLY 0.60 | Peers 0.54 | |||||||||||||||||||||
|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations. LLY is trading at a significant premium to its peers. |
Premium. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. LLY trades at a premium to its peers. |
|||||||||||||||||||||||
| Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
| LLY 6.13 | Peers 19.66 | LLY 20.20 | Peers -20.56 | |||||||||||||||||||||
|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. LLY is trading at a significant discount to its peers. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. LLY is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
| Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
| LLY 4.35 | Peers 12.73 | LLY 5.01 | Peers 5.56 | |||||||||||||||||||||
|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. LLY is trading at a significant discount to its industry on this measurement. |
Average. Comparing a company's sales growth to its industry helps to determine if the company is adding or losing market share. LLY is keeping pace with its peers on the basis of sales growth. |
|||||||||||||||||||||||
